福元医药(601089) - 2025 Q3 - 季度财报

Financial Performance - Total revenue for Q3 2025 was CNY 886,633,876.55, a decrease of 0.55% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 107,472,743.41, down 2.59% year-on-year[4] - Basic and diluted earnings per share were both CNY 0.22, reflecting an 8.33% decline compared to the previous year[5] - Total revenue for the first three quarters of 2025 was RMB 2,520,605,126.57, a slight decrease from RMB 2,547,022,297.14 in the same period of 2024, representing a year-over-year decline of approximately 1.0%[19] - Net profit attributable to shareholders was CNY 375,340,383.05, down 6.4% from CNY 400,949,905.30 in the prior period[21] - Operating profit for the period was CNY 422,648,243.33, slightly down from CNY 435,280,857.09, reflecting a decrease of 2.9%[20] - The company reported a net profit margin of approximately 10.0% for the first three quarters of 2025, consistent with the previous year's performance[19] Cash Flow and Assets - Operating cash flow for the year-to-date period decreased by 35.88% to CNY 314,171,729.27[9] - The company experienced a decrease in cash flow primarily due to a reduction in interest income and an increase in expenses[9] - Cash flow from operating activities generated a net amount of CNY 314,171,729.27, a significant decrease of 35.9% compared to CNY 490,004,394.07 in the previous period[25] - Cash flow from investing activities showed a net inflow of CNY 851,307,874.73, contrasting with a net outflow of CNY 1,568,523,571.52 in the prior period[26] - The company reported a total cash and cash equivalents balance of CNY 1,588,816,104.22 at the end of the period, up from CNY 973,786,073.63 in the previous period[26] - The company's cash and cash equivalents increased significantly to RMB 1,589,127,104.22 from RMB 794,067,803.65, reflecting a growth of approximately 100%[15] Assets and Liabilities - Total assets at the end of the reporting period were CNY 4,793,008,534.64, a decrease of 0.49% from the end of the previous year[5] - As of September 30, 2025, total current assets amounted to RMB 2,958,350,115.16, down from RMB 3,201,162,514.77 at the end of 2024, indicating a decrease of about 7.6%[15] - Total liabilities decreased to RMB 1,093,684,239.30 from RMB 1,260,550,997.56, showing a reduction of approximately 13.2%[17] - The total equity attributable to shareholders increased to RMB 3,685,349,376.74 from RMB 3,544,556,038.10, representing a growth of about 4.0%[17] - Shareholder equity attributable to the parent company increased by 3.97% to CNY 3,685,349,376.74[5] Shareholder Information - The company reported a total of 22,691 common shareholders at the end of the reporting period[10] - The top three shareholders held a combined 71.85% of the shares, with New Hecheng Holding Group owning 36.73%[11] - The company has not engaged in any share repurchase activities during the reporting period[13] - There were no changes in the participation of major shareholders in margin financing and securities lending activities[13] Operational Insights - Total operating costs for the period were CNY 2,120,432,691.61, a decrease of 1.1% compared to CNY 2,143,616,163.40 in the previous period[20] - Research and development expenses amounted to CNY 276,839,281.61, a decrease of 7% from CNY 297,591,745.37 in the previous period[20] - Sales revenue from goods and services received cash of CNY 2,416,292,559.89, down 4% from CNY 2,516,657,281.73 in the prior period[25] - The company plans to continue focusing on market expansion and new product development in the upcoming quarters[19] - Inventory levels rose to RMB 383,407,211.04 from RMB 347,555,462.41, marking an increase of about 10.3%[15] - The company experienced a net cash increase of CNY 875,056,300.57, contrasting with a net decrease of CNY 1,530,714,290.45 in the previous period[26] - Non-operating income included government subsidies of CNY 2,010,076.14 for the current period[7]